Meeting
2014 ASCO Annual Meeting
A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
Authors
Razelle Kurzrock
University of California, San Diego, La Jolla, CA
Razelle Kurzrock , Evanthia Galanis , Derek Richard Johnson , Vikram Kansra , Keith Wilcoxen , Ty Mcclure , Robert E. Martell , Shefali Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01294735
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2092)
DOI
10.1200/jco.2014.32.15_suppl.2092
Abstract #
2092
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A study of senaparib in combination with temozolomide for the treatment of patients with advanced solid tumors and extensive-stage small cell lung cancer.
First Author: Bo Gao
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
First Author: Daniel E. Castellano